Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)44.45
  • Today's Change-0.50 / -1.11%
  • Shares traded7.31k
  • 1 Year change+21.12%
  • Beta--
Data delayed at least 15 minutes, as of Nov 05 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Orion Oyj, previously Orion Corporation, is a Finland-based company active within the pharmaceutical industry. The Company is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.

  • Revenue in EUR (TTM)1.43bn
  • Net income in EUR331.80m
  • Incorporated2006
  • Employees3.82k
  • Location
    Orion OyjOrionintie 1AESPOO 02200FinlandFIN
  • Phone+358 104261
  • Fax+358 104264435
  • Websitehttps://www.orion.fi/
More ▼

Institutional shareholders

9.12%Per cent of shares held by top holders
HolderShares% Held
Keskin�inen El�kevakuutusyhti� Ilmarinenas of 21 Jun 20231.85m5.60%
Keskin�inen Ty�el�kevakuutusyhti� Eloas of 28 Feb 2023292.80k0.89%
Guardians of New Zealand Superannuationas of 30 Jun 2023223.39k0.68%
Dimensional Fund Advisors LPas of 03 Oct 2024128.37k0.39%
Jenny ja Antti Wihurin rahasto sras of 28 Feb 2023123.84k0.38%
Handelsbanken Fonder ABas of 30 Sep 2024119.31k0.36%
abrdn Investment Management Ltd.as of 31 Jan 2024115.93k0.35%
Mercer Global Investments Europe Ltd.as of 31 Dec 202375.06k0.23%
Nordea Investment Management AB (Denmark)as of 30 Aug 202450.24k0.15%
BlackRock Investment Management (UK) Ltd.as of 31 Mar 202432.43k0.10%
More ▼
Data from 30 Jun 2023 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.